23 patents
Utility
Methods of Treating Neuromyelitis Optica Spectrum Disorder
21 Dec 23
Methods of treating neuromyelitis optica spectrum disorder (NMOSD) are disclosed herein.
William REES, Eliezer KATZ, Michael SMITH, Nanette MITTEREDER
Filed: 28 Dec 22
Utility
Use of an ANTI-CD19 Antibody to Treat Autoimmune Disease
14 Sep 23
Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein.
Dewei SHE, John Nolan RATCHFORD, Eliezer KATZ, William A. REES
Filed: 19 Apr 23
Utility
Immunocytokines for Treatment of Autoimmune and Inflammatory Conditions
7 Sep 23
Abstract: The present disclosure is directed to fusion proteins comprising a Tumor Necrosis Factor α (TNFα) binding protein and an interleukin-10 (IL-10) molecule, methods of making the fusion proteins, and methods of treating or preventing autoimmune and inflammatory conditions using the fusion proteins.
Partha S. CHOWDHURY, Yong-Jun LIU, Shino HANABUCHI, Nazzareno DIMASI
Filed: 20 Jul 21
Utility
Binding molecules specific for FcγRIIA and uses thereof
5 Sep 23
The disclosure provides FcγRIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting FcγRIIA activity, and methods of using the FcγRIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
Filed: 1 Mar 22
Utility
ILT7 Binding Molecules and Methods of Using the Same
10 Aug 23
The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
Katherine Ann VOUSDEN, Julie Ann DOUTHWAITE, Melissa Marie DAMSCHRODER, Miguel Angel SANJUAN
Filed: 21 Apr 23
Utility
Compositions Comprising a TN3 Scaffold and Methods of Using the Same
3 Aug 23
The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L.
Anthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David Kenneth SPENCER
Filed: 1 Nov 22
Utility
Methods of Treating Immune Mediated Pulmonary Injury
18 May 23
The present disclosure relates to methods for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject in need thereof, the method comprising administering to the subject an anti-Type I interferon (anti-T1i) therapy that blocks the activity, function or production of Type I interferon (T1i) in the subject, wherein the anti-T1i therapy is administered to the subject infected with a respiratory virus that causes a delayed T1i response in the subject.
Gabor ILLEI, William Rees, Jorn Drappa
Filed: 30 Sep 22
Utility
Antibodies to Feline Mcdonough Sarcoma (Fms)-like Tyrosine Kinase 3 Receptor Ligand (FLT3L) and Uses Thereof for Treating Autoimmune and Inflammatory Diseases
23 Feb 23
Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases.
Anna HANSEN, Xiao Xiaodong, Peter Pavlik, Yan Chen, Catherine Rachel Ettinger
Filed: 21 Jul 22
Utility
Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer
17 Jan 23
The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L.
Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
Filed: 28 Jul 21
Utility
Methods of Treatment Using ILT7 Binding Proteins
22 Dec 22
The present disclosure is related to methods of treating autoimmune disorders in a subject comprising administering immunoglobulin-like transcript 7 (ILT7) binding proteins to a subject having elevated type I interferon gene signature (IFNGS).
William REES, John N. RATCHFORD, Jodi KARNELL, Jorn DRAPPA, Gabor ILLEI
Filed: 3 Jun 22
Utility
Binding Molecules Specific for Fcgamma Riia and Uses Thereof
1 Dec 22
The disclosure provides FcγRIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting FcγRIIA activity, and methods of using the FcγRIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
Filed: 1 Mar 22
Utility
Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
29 Nov 22
Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases.
Anna Hansen, Xiao Xiaodong, Peter Pavlik, Yan Chen, Catherine Rachel Ettinger
Filed: 13 Feb 19
Utility
Use of an ANTI-CD19 Antibody to Treat Autoimmune Disease
30 Jun 22
Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein.
Eliezer KATZ, Jorn DRAPPA, Kathleen MCKEEVER
Filed: 23 Apr 20
Utility
ILT7 Binding Molecules and Methods of Using the Same
12 May 22
The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
Katherine Ann VOUSDEN, Julie Ann DOUTHWAITE, Melissa Marie DAMSCHRODER, Miguel Angel SANJUAN
Filed: 17 Jun 21
Utility
Binding molecules specific for FcγRIIA and uses thereof
19 Apr 22
The disclosure provides FcγRIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting FcγRIIA activity, and methods of using the FcγRIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
Filed: 28 Apr 17
Utility
Nucleic Acids Encoding a TN3 Scaffold Comprising a CD40L-SPECIFIC Monomer Subunit
24 Mar 22
The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L.
Anthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David SPENCER
Filed: 28 Jul 21
Utility
CD40L Antagonist and Uses Thereof
4 Nov 21
A human CD40L-specific Tn3 molecule and therapeutic uses thereof.
Jorn DRAPPA, Marius ALBULESCU, Jing LI, Ethan GRANT, Katie STREICHER, Gabor ILLEI, Liangwei WANG, William REES
Filed: 25 Sep 19
Utility
Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit
31 Aug 21
Anthony Coyle, Manual Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
Filed: 31 May 18
Utility
ILT7 binding molecules and methods of using the same
27 Jul 21
The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.
Katherine Ann Vousden, Julie Ann Douthwaite, Melissa Marie Damschroder, Miguel Angel Sanjuan
Filed: 9 Mar 17
Utility
Humanized ANTI-CD19 Antibodies and Their Use In Treatment of Oncology, Transplantation and Autoimmune Disease
4 Mar 21
The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies.
Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
Filed: 26 May 20